Leo Pharma to launch new growth driver in Q4 — will start in Germany
Leo Pharma believes that JAK inhibitor delgocitinib can become a significant growth driver, and the dermatology expects to launch it in Europe at the end of the year.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.